CLINICAL_TRIALS
trial_result
· 2015-03-20
Clinical Trial Update: Study of Immunotoxin, MR1-1 [Phase 1]
Summary
Phase 1 study of the immunotoxin MR1-1 for supratentorial malignant brain tumors has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Darell D. Bigner, MD, PhD | Conditions: Supratentorial Malignant Brain Tumor | Phase 1 | Status: TERMINATED